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Transplant (NHSBT), Bristol, United KingdomSummary IntroductionPrimary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC)
and autoimmune hepatitis (AIH) represent the three major autoim-
mune liver diseases (AILD). PBC, PSC, and AIH are all complex disor-
ders in that they result from the effects of multiple genes in
combinationwith as yet unidentiﬁed environmental factors. Recent
genome-wide association studies have identiﬁed numerous risk loci
for PBC and PSC that host genes involved in innate or acquired
immune responses. These loci may provide a clue as to the
immune-based pathogenesis of AILD. Moreover, many signiﬁcant
risk loci for PBC and PSC are also risk loci for other autoimmune dis-
orders, such type I diabetes, multiple sclerosis and rheumatoid
arthritis, suggesting a shared genetic basis and possibly similar
molecular pathways for diverse autoimmune conditions. There is
no curative treatment for all three disorders, and a signiﬁcant num-
ber of patients eventually progress to end-stage liver disease requir-
ing liver transplantation (LT). LT in this context has a favourable
overall outcome with current patient and graft survival exceeding
80% at 5 years. Indications are as for other chronic liver disease
although recent data suggest that while lethargy improves after
transplantation, the effect is modest and variable so lethargy alone
is not an indication. In contrast, pruritus rapidly responds. Cholangi-
ocarcinoma, except under rigorous selection criteria, excludes LT
because of thehigh risk of recurrence. All three conditionsmay recur
after transplantation and are associated with a greater risk of both
acute cellular and chronic ductopenic rejection. It is possible that a
crosstalk between alloimmune and autoimmune response perpetu-
ate each other. An immunological response toward self- or allo-
antigens is well recognised after LT in patients transplanted for
non-autoimmune indicationsandsometimes termed ‘‘denovoauto-
immune hepatitis’’.Whether this is part of the spectrumof rejection
or an autoimmune process is not clear.
In thismanuscript,we reviewnovelﬁndings aboutdiseaseprocesses
and mechanisms that lead to autoimmunity in the liver and their
possible involvement in the immune response vs. the graft after LT.
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E-mail address: James.Neuberger@nhsbt.nhs.uk (J.M. Neuberger).Autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and
primary sclerosing cholangitis (PSC) are the tree major forms of
autoimmune liver disease, which differ according to the focus
of autoimmune injury, the pattern of inﬂammation and the clin-
ical phenotype.
In AIH, the autoimmune injury affects the hepatocytes, lead-
ing to the histological picture of interface hepatitis. In PBC, the
autoimmune injury affects the small, interlobular bile ducts,
causing the typical appearance of non-suppurative, destructive
cholangitis. In PSC, autoimmune or immune-mediated injury
affects the medium-sized intra- and extrahepatic bile ducts, caus-
ing concentric and obliterative ﬁbrosis and multifocal bile duct
stricturing.
AIH, PBC, and PSC represent complex disorders, in that they
result from the interaction between genetic and environmental
factors (Fig. 1). In recent years, there have been major efforts to
delineate the genetic architecture of these conditions. Recent
genome-wide association studies (GWAS) and iCHIP-association
studies [1–8] identiﬁed numerous risk loci for PBC and PSC that
host genes involved in innate or acquired immune responses.
These ﬁndings have resulted in a better understanding of the
pathogenic mechanisms underlying these immune-mediated
conditions, highlighting common immune pathways between
clinically associated disorders and explaining the tendency for
patients and their families to suffer from multiple autoimmune
conditions. This translates in the possibility of unique immuno-
logic pathways for therapeutic intervention. The implication is
that biological processes involved in loss of immune tolerance
to one self-antigen (such as CYP2D6 in the case of some models
of AIH or PDC-E2 in PBC) might be the same for other self-anti-
gens (such as thyroid peroxidase in thyroid disease).
All three disorders have a progressive course that, if
untreated, develop into liver failure requiring liver transplanta-
tion (LT). The aim of treatment is to abolish or reduce inﬂamma-
tion, cholestasis and progression of ﬁbrosis. Standard therapy in
AIH consists of a combination of corticosteroids and azathioprine,
which is effective in 80% of patients; however progression may
occur despite seemingly effective treatment. Other immunosup-
pressive agents such as mycophenolate mofetil, d-penicillamine,
sirolimus and anti-T cell therapies have been tried in refractory
cases with limited success [9]. The only licensed therapy for
PBC and PSC is ursodeoxycholic acid (UDCA) [10]. In PBC,











Fig. 1. AIH, PBC, and PSC are complex disorders meaning they are likely associated with the effects of multiple genes in combination with environmental factors.
JOURNAL OF HEPATOLOGYand progression of ﬁbrosis; those who do not respond to UDCA
have a poor survival (10-year survival is >95% and <80% in
responders and non-responders to UDCA, respectively) [11].
Other drugs including methotrexate, colchicine and ﬁbrates, have
been tested in combination with UDCA but none has been found
to be of beneﬁt [12–18]. A promising agent, under investigation is
Obeticholic acid (OCA); this is a novel bile acid, which is an ago-
nist of the Farsenoid X receptor implicated in the metabolism and
enterohepatic circulation of bile acids [19].
In PSC, treatment with UDCA improves serum liver tests but
does not improve survival; indeed, higher doses (17–23 mg/kg/
day) are associated with high rates of serious adverse events
[20]. Although some units no longer routinely advise their
patients with PSC to take UDCA, recent data from the analysis
of the UK-PSC cohort [21] of around 700 patients, have shown a
dose dependent effect of UDCA on LT-free survival (UK-PSC –
unpublished data). Thus, for these autoimmune liver diseases
there is a subgroup of patients who are non-responders to cur-
rent treatments and have a poor prognosis, for whom new ther-
apeutic options are warranted. However, development of novel
agents is currently hindered by inadequate understanding of
the aetiology and pathogenesis of these autoimmune conditions.Clinical phenotypes of autoimmune liver disease
Clinical and immunological features suggest that AIH is an arche-
typal autoimmune condition. It is characterized by a strong
female preponderance (F:M ratio 7:1); hypergammaglobulina-
emia; seropositivity for autoantibodies and a good clinical, sero-
logical and histological response to corticosteroids. Furthermore,
in AIH concurrent autoimmune disorders occur in approximately
40% of patients, particularly autoimmune thyroid disorder (AITD).
Two types of AIH are recognised: type 1 (AIH-1), characterised
by antinuclear antibodies (ANA) and/or anti-smooth muscleJournal of Hepatology 201antibody (SMA), and type 2 (AIH-2), characterised by anti-liver
kidney microsomal type 1 antibody (anti-LKM-1) or for anti-liver
cytosol type 1 antibody (anti-LC-1) [22].
PBC also exhibits a number of autoimmune features, including
the presence of autoreactive T cell and B cell responses against
mitochondrial self-antigens, in particular the E2-domain of pyru-
vate dehydrogenase complex (PDC-E2); the almost universal
presence of auto-antibodies reactive with mitochondrial self-
antigens; a strong female predominance (F:M ratio, 10:1) and
an association with other autoimmune diseases in the same indi-
vidual and their close family. A concurrent autoimmune disorder
occurs in between 32% and 53% of patients, most notably AITD,
systemic lupus erythematosus (SLE) or systemic sclerosis (SSc)
[23,24]. Autoimmunity is also common in families of PBC
patients, with an estimated 14–20% of ﬁrst degree relatives of
PBC probands having an autoimmune disease other than PBC
[25,26]. However, unlike AIH, no immunosuppressive agent to
date has been shown to be effective in PBC.
PSC is considered an ‘autoimmune disease with atypical fea-
tures’ because it displays several differences when compared
with the classical autoimmune diseases: these include male pre-
dominance (M:F ratio, 2:1), the absence of disease-speciﬁc auto-
antibodies, and the poor response to immunosuppression.
However, features that suggest an immune-mediated origin
include the major contribution of risk variants within the human
leukocyte antigen (HLA) complex, the presence of non-speciﬁc
autoantibodies, including atypical anti-neutrophil cytoplasmic
antibodies (ANCA) [27], the preferential usage of speciﬁc T cell
receptor variable chains implying the presence of a speciﬁc
(self)-antigen [28], and a strong association with other autoim-
mune or immune-mediated disorders which occur in approxi-
mately 70% of patients. Most notable is a form of inﬂammatory
bowel disease (IBD), sometimes termed IBD-PSC, which affects
up to 90% of patients [29,30]. IBD without any sign of PSC occurs
more frequently among ﬁrst degree relatives of patients with PSC.4 vol. 60 j 210–223 211
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IBD in those with PSC tends to have a different phenotype com-
pared with IBD alone. Approximately 25% of PSC patients have
an autoimmune condition outside of the gastrointestinal tract,
most commonly type I diabetes mellitus (T1DM) or AITD [31].
Shared serological, immunological and histological patterns
exist across the spectrum of AIH, PBC, and PSC. Conditions exhib-
iting features of two different autoimmune liver diseases are
commonly designated ‘overlap syndromes’. These are repre-
sented by variant forms of AIH, in which there are characteristics
of both AIH and PBC (‘AIH/PBC overlap’) or AIH and PSC (‘AIH/PSC
overlap’). Whether these represent distinct entities or part of a
disease spectrum ranging from pure PBC’/‘pure PSC at one
extreme to ‘pure AIH’ at the other, is not clear. Despite genetic
susceptibility loci for these diseases being strongly linked to the
HLA region, these are generally distinct across all three disease
entities. Intriguingly, there is barely any signiﬁcant genetic over-
lap between PBC and PSC. Indeed, clinical overlap of PBC and PSC
is not a well-recognized entity.Recent highlights from high-throughput genetic studies of
autoimmune liver disease
In the last decade, there have been major efforts in Europe, North
America and Japan to establish large, well-characterised patient
cohorts for high-throughput genetic studies of PBC and PSC,
and to a lesser extent, AIH. Four GWAS [1–4] and two iCHIP-asso-
ciation [5,6] studies of PBC have been published; and two GWAS
of PSC followed by a number of replication studies, and a recent
iCHIP association study of PSC [7,8,21,32–35]. High-throughput
genetic studies have revolutionized the study of complex dis-
eases, changed the genetic landscape of autoimmune liver dis-
ease and highlight the shared genetic basis of diverse
autoimmune conditions. Risk loci for PBC and PSC appear to be
enriched for gene products involved in innate or acquired
immune responses, consistent with an autoimmune component
to pathogenesis. However, more work is required to conﬁrm can-
didate genes, to evaluate the functional consequences of risk vari-
ants and to understand how functional changes contribute to
disease-speciﬁc pathologies.
GWAS have clearly demonstrated that the major component
of the genetic architecture of PBC and PSC is within the HLA
region. As expected in a genetically complex disease, GWAS also
identiﬁed several novel non-HLA variants, but all lie in immuno-
related genes. In PBC, candidate genes are potentially involved in
regulation of the immune system, from the development and dif-
ferentiation of the myeloid cell compartment (SPIB, IRF5, IRF8,
and IL-7R) to antigen presentation and T cell differentiation (class
II HLA, CD80, IL12, IL12R, TYK2, STAT4, SOCS1) up to B cell function
(SPIB, IRF8, PLC-L2, SPIB, PLC-L2, IKZF3, CXCR5). In PSC, there is an
overwhelming contribution to disease risk by the HLA (in partic-
ular HLA class I genes HLA-B and HLA-C). The immunological
implications of the PSC associated HLA variants are not entirely
clear. It is possible there is a protective effect of the HLA-C2 killer
immunoglobulin receptors (KIRs) ligand variant on PSC develop-
ment [36]. The non-HLA ﬁndings in PSC to some extent indicate
that the proposed hypotheses on PSC pathogenesis related to
autoimmune mechanisms (IL2 and IL2RA), bile acid toxicity
(GPBAR1), and mechanisms related to the concomitant IBD (IL2/
IL21, IL2RA, REL etc.) might operate in concert to cause the
disease.212 Journal of Hepatology 201However, more work is required to conﬁrm candidate genes,
to evaluate the functional consequences of risk variants and to
understand how functional changes contribute to disease-speciﬁc
pathologies.
A GWAS of AIH in European and Japanese cohorts are under-
way and results from these studies will be reported by 2014.
GWAS typically identify common genetic variants with small
effect sizes, leading to incomplete tagging of rarer variants with a
potentially higher phenotypic impact. Also, GWAS have identiﬁed
only a small number of the causal variants for recently identiﬁed
genetic loci (mainly intronic and intergenic) which, in turn, inter-
pret only a small part of the genetic contribution to these dis-
eases (i.e., ‘missing heritability’). To identify the rare genetic
variants and explain the missing heritability sequencing the use
of emerging platform is required. Whole-genome and whole-
exome sequencing (which focuses on the protein-coding exons
and exon/intron boundaries containing splicing signals) are
becoming increasingly available but present signiﬁcant chal-
lenges with respect to data analysis, interpretation, and display.
Integration of the other comprehensive ‘‘-omics’’ methodologies
into the analysis of genetic variants may help to explain their
potential effects. Transcriptomics aims to elucidate the tran-
scripts of the genome or gene expression levels on the RNA level
under varying conditions; genomics/transcriptomics screens can
yield information on both gene expression and alternative splic-
ing and can help to identify previously unknown genes. Finally,
proteomics studies the proteome in a cell compartment, tissue
or organism comprising all proteins that are encoded in the gen-
ome and represents the next step in the study of biological sys-
tems [37,38]. Studying the genome/proteome in AILD will shed
light on common and distinct pathological pathways leading to
AILD.
As with translation of many genomic discoveries, translating
this work into direct health beneﬁts will require interaction
among a wide array of biomedical disciplines, including genom-
ics, molecular biology, clinical medicine, pharmacology and
bioinformatics.Shared genetic basis of different autoimmune diseases
An emerging theme in the genetics of complex disorders is the
considerable overlap of genetic susceptibility factors between
related diseases. The recent PSC iCHIP study [8] has revealed
strong positive correlation of 44 non-HLA loci identiﬁed in GWAS
of seven clinically associated autoimmune disorders, including
ulcerative colitis (UC), Crohn’s disease (CD), T1DM, coeliac dis-
ease (CeD), psoriasis, rheumatoid arthritis (RA) and sarcoidosis,
suggesting close similarity in the genetic architecture of PSC
and each of these conditions. Of these loci, 11 achieved gen-
ome-wide signiﬁcance and 33 loci achieved suggestive signiﬁ-
cance (p <5  105) in the standard test of association.
Functional network analysis showed that candidate genes at
pleiotropic loci were related in terms of their function, highlight-
ing common pathways involved in the pathogenesis of PSC and
clinically associated disorders. These observations suggest there
might be distinct mechanisms by which autoimmunity occurs,
each mechanism predisposing to a particular phenotype or set
of phenotypes. This might also suggest that there might be
unique immunologic pathways that we have to focus on for ther-
apeutic intervention (Fig. 2).4 vol. 60 j 210–223
Fig. 2. Network map showing complexity of shared genetic effects. Some shared risk loci are involved in the pathogenesis of several autoimmune disorders. These loci
are clustered in the centre of the ﬁgure. Other shared risk loci are associated with only two conditions. Numerous risk loci are associated with a single disorder. It is
plausible that the central loci associated with numerous conditions are those involved in autoimmunity in general, whereas risk loci speciﬁc to a given disease determine
the particular phenotype. AITD, autoimmune thyroid disease; AS, ankylosing spondylitis; CeD, coeliac disease; CD, Crohn’s disease; PSC, primary sclerosing cholangitis; MS,
multiple sclerosis; PBC, primary biliary cirrhosis; RA, rheumatoid arthritis; SLE, Systemic lupus erythematosus; SS, systemic sclerosis; T1DM, type 1 diabetes mellitus; UC,
ulcerative colitis. Reproduced from [156]. With permission from the Editor in Chief Prof. Eric M. Gershwin.
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risk variants of genes across a wide range of autoimmune dis-
eases implies that the common variants identiﬁed through GWAS
are not particularly helpful in explaining the organ-speciﬁc man-
ifestation of a given autoimmune trait. The most likely explana-
tion for the ambiguity of the genetic ﬁndings is that
phenotypes might be the result of gene-gene interaction (epista-
sis) or gene-environment interaction. From this perspective, the
study of the ‘exposome’, which represents the environmental fac-
tors which we are exposed to in a lifetime, represents a cutting-
edge tool in the study of autoimmunity [39]; the study of the
exposome needs to address exogenous factors, such as tobacco
smoke, diet, drugs, occupational exposures, environmental pollu-
tants, ultraviolet radiation, heavy metal, and endogenous factors
related to the environment, including by-products of inﬂamma-
tion, lipid peroxidation and oxidative stress [40]. Some of these
components may act as nucleophiles or electrophiles, and as
such, would be capable of DNA and protein modiﬁcation [41].Journal of Hepatology 201Recent studies in T2DM have shown that the exposome can
indeed be measured and characterized using environmental-
wide association studies (EWAS), where epidemiological data
are comprehensively interpreted in a manner similar to GWAS
[42]. Growing interest in the ﬁeld of autoimmune diseases is in
the exploration of the ‘infectome’, which is the part of the expo-
some referring to the collection of an individual’s infectious expo-
sures, which are associated with the disease. An autoimmune
disease can be induced or triggered by infectious agents. In many
cases, it is not a single infection but rather the ‘burden of infec-
tions’ from childhood that is responsible for the induction of
autoimmunity. In contrast, the hygiene hypothesis underlines
the protective role played by infections [39]. Further hints
regarding infective factors potentially involved in the develop-
ment of or protection against autoimmunity can be provided by
the study of the ‘microbiome’, deﬁned as the community of com-
mensal, symbiotic, and pathogenic microorganisms that share
our body space. For example, in the case of PBC, it may be4 vol. 60 j 210–223 213
Table 1. Transplant activity and survival for autoimmune liver diseases in two different eras (1988–2001 and 2000–2009) in Europe. The number of LT for AIH and PSC
has remained stable over the time while the number of LT for PBC, despite the rise in the prevalence of the disease, has declined.
From Jan 1988 to Dec 2001 From Jan 2000 to Dec 2009
Disease No. 
patients
% Survival No. 
patients
% Survival
1 yr 5 yr 10 yr 1 yr 5 yr
Patient Graft Patient Graft Patient Graft Patient Graft Patient Graft
Autoimmune 
hepatitis
991 3 81 76 72 65 65 58 1069 2 88 84 80 72
Primary biliary 
cirrhosis
2959 8 83 79 77 71 69 64 1929 4 90 85 83 78
Primary sclerosing 
cholangitis
1731 4 83 78 75 65 66 54 2170 5 90 83 82 72
European Liver Transplant Registry report [45,145].
Frontiers in Liver Transplantationpertinent to understand the normal microbiome of the urinary
bladder and vagina, as infections in these sites have been associ-
ated with PBC [43].
Studying the role of thedifferent aspects of the exposome in the
development of autoimmune diseases could complement classical
immunological research tools and GWAS. Several factors suggest
that PBCmay represent an idealmodel disease for the investigation
of the role of the exposome: its relatively high prevalence com-
pared to other immunologic diseases; the well-known evidence
in support of a combination of genetic, environmental, and infec-
tious factors involved in the pathogenesis of the disease; the
variability of its natural history, which suggests the presence of
high-risk and low-riskpatients; the associationwith other autoim-
mune diseases; and the lack of need of immunosuppression,which
might impair the immunological assessment of the ‘infectome’
(the infective component of the exposome). More recently, there
is indicative evidence that in addition to genetics, other comple-
mentary mechanisms are involved in the pathogenesis of autoim-
munity, in particular, epigenetics – deﬁned as stable and heritable
patterns of gene expression caused by mechanisms other than
changes in the underlying DNA sequence. Epigenetic mechanisms
primarily consist of DNA methylation, histone modiﬁcations and
small non-coding RNA transcripts. Epigenetic marks can be
affected by age and other environmental triggers, and can there-
fore provide a plausible link between environmental factors and
the onset and development of autoimmune liver disease [44].
Below, we review the basis of the autoimmune response toward
thegraft inpatientswith andwithoutpreviousautoimmunedisease
and examine the current evidence on mechanisms that lead to the
autoimmunity and their link to transplant rejection.Liver transplantation for autoimmune liver disease
AIH, PBC, and PSC represent three major indications for liver
transplantation (LT) in Western countries [45]. Paradoxically,
the rise in the documented prevalence of PBC [46] contrasts with
the fall in the transplant rate (Table 1). Reasons for this decline
are not clear but may relate to a changing pattern of disease,
increased rates of diagnosis, more effective treatment or other
causes. The proportion LTs for AIH and PSC has remained stable
(2% and 4%, respectively); in some areas, such as in the Scandina-
vian countries, which have a relatively low prevalence of hepati-
tis C and alcoholic liver disease (ALD), PSC is the leading
indication accounting for 16% of the LT [47]. LT in AILD is indi-
cated when liver failure occurs with complications similar to
those for end-stage liver disease caused by other aetiologies. An214 Journal of Hepatology 201unacceptable quality of life because of severe, treatment-resis-
tant pruritus or severe hepatic encephalopathy may also merit
consideration for transplantation. Fatigue in PBC and other chole-
static liver diseases is often severe and disabling. Cross-sectional
studies have shown no evidence of improved fatigue after LT
[48,49]. We have recently shown, in a single-centre, prospective,
longitudinal cohort that fatigue improves after LT. However, 44%
of the 31 patients had moderate to severe fatigue at two years
after LT. Whether this improvement is enough to justify organ
allocation in patient with fatigue alone, without liver failure,
remains still an open issue [50].
Recurrent cholangitis related to dominant strictures or intra-
hepatic strictures not amenable to dilatation and stenting in
PSC rarely represent indication for LT. Cholangiocarcinoma
(CCA) may complicate PSC, with a 10-year incidence of 7–9%
[51]. Risk factors for CCA include advanced disease (elevated bil-
irubin, variceal bleeding), proctocolectomy, chronic ulcerative
colitis with colorectal cancer or dysplasia, long history of inﬂam-
matory bowel disease, and polymorphisms of the NKG2D gene
[52–54]. Historically, the presence of such a tumour contra-indi-
cates LT because of the high rate of recurrence. However, studies
from the Mayo Clinic suggest that in highly selected cases,
aggressive treatment with chemo- and radiotherapy may allow
some patients to have a good outcome (54). Hepatocellular carci-
noma (HCC) occurs in patients with AILD with cirrhosis, with a
variable incidence (AIH: 1.9% per year [55]; PBC 4% – 12.3 at
10 years [56–58]; PSC: 2% per year [59,60]) and represents an
indication for LT. The prioritization of these patients for LT is
the same as for other liver diseases associated with HCC.
Outcomes after LT for AILD are generally excellent (Table 1).
Speciﬁc post-transplant issues in patients transplanted for AILD
are recurrence of the original disease and a higher rate of rejec-
tion, which may both impact on survival. Furthermore, PSC trans-
plant recipients with concomitant IBD are more likely to develop
colon cancer, with a cumulative incidence at 10 years after LT of
8.2% [61]. Routine surveillance colonoscopy is therefore usually
recommended.Recurrence of autoimmune liver disease after liver
transplantation
Autoimmune liver disease might be expected not to recur after LT
as the grafts should be protected from such injury from the outset
by levels of immunosuppression that prevents allograft rejection.
However, AIH, PBC, and PSC recur in many recipients and recur-
rence may be more aggressive than the original disease (Table 2).4 vol. 60 j 210–223
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RecurrentAIH (rAIH) is reported inabout23%and isdiagnosedat
a median interval of 26 months, but recurrence after more than
10 years after transplant and in those taking17.5–20 mgof prednis-
olone per day, has been reported. rAIH may be seen with normal
liver tests so the use of protocol biopsymay identify thosewith clin-
ically silent recurrence [62]. Histological features of rAIH include a
mononuclear inﬁltrate of lymphocytes and plasma cells extending
fromportal tracts to lobular parenchyma and an absence of features
of acute rejection such as endothelialitis and ductulitis. There is
some evidence that corticosteroid withdrawal does not precipitate
rAIH [63], although recurrence is often responsive to an introduc-
tion of, or an increase in the dose of corticosteroids.
The diagnosis of recurrent PBC (rPBC) is made on histological
criteria since liver tests are nonspeciﬁc and AMA persist irrespec-
tive of evidence of graft histology. The reported prevalence rate
of rPBC ranges from 0% to 35%. The reported incidence rate is 21–
37% at 10 years and 43% at 15 years [62]. The median time to rPBC
ranges between 3 and 5.5 years. The reported recurrence fre-
quency rate increases with time and varies in part because of dif-
ferent diagnostic criteria as well as different policies for protocol
biopsies, since recurrence may be present with normal liver tests.
Because of the beneﬁcial effect of UDCA in slowing the progression
of PBC in the native liver, this is commonly offered to those with
evidence of rPBC. However, the assessment of drug efﬁcacy is chal-
lenging as many patients have normal or near normal liver tests at
diagnosis; the current data, which are limited, suggest that UDCA
does not seem to inﬂuence patient and graft survival [64].
PSC has been shown to recur between 10% and 27%, with a
mean interval between LT and onset of 6 months to 5 years
[62]. Recurrent PSC (rPSC) needs to be distinguished from sec-
ondary sclerosing cholangitis. There are several causes of second-
ary sclerosing cholangitis, including hepatic artery thrombosis,
ischemic and ischemia/reperfusion injury, infection with CMV
or HIV, ABO incompatibility and rejection; the diagnosis is made
on showing multiple non-anastomotic strictures with no other
risk factors. There is no established medical therapy for rPSC.
UDCA may be of beneﬁt in those with coexisting UC, as some sug-
gest it reduces the risk of colon cancer [65]. Interventional chol-
angiographic treatment of biliary strictures should be considered
when dominant strictures are present; however, such approaches
are rarely feasible since most strictures are multiple and most
recipients have a Roux loop (since the disease affects both the
intra- and extra-hepatic bile ducts). Therefore,magnetic resonance
imaging (MRI) is often used to diagnose or exclude rPBC although
percutaneous transhepatic cholangiography (PTC) allows both diag-
nostic and, in some cases, therapeutic intervention. Recent series
report the successful use of single and double balloon enteros-
copy in patients with roux loop [66,67].
Immunosuppressive strategies to reduce the risk of recur-
rence of AILD are difﬁcult to be evaluated since majority of stud-
ies are retrospective and detailed information, including changes
in immunosuppression and disease stage where the change of
medication took place, are missing.
Graft loss due to recurrent disease is not a major issue in PBC,
but it is in AIH and PSC (percentage of graft lost due to recurrent
disease: 1.3% in PBC; 6.2% in AIH; and 8.4% in PSC) [68]; the rate
of graft loss from rAIH may be falling because of increasing long-
term use of corticosteroids in these patients.
LT provides a unique setting to help understand the patho-
physiology of autoimmune liver diseases. Using protocol fol-
low-up and liver biopsies to pinpoint the onset of disease, itJournal of Hepatology 201might be possible to elucidate the innate and adaptive immune
processes active at the earliest stage of disease. In practical terms,
this is not easily achieved since the majority of centres have dis-
continued the practice of protocol liver biopsies in allograft recip-
ients other than HCV.
Risk factors for recurrent AILD
Assessment of risk factors for recurrence of AILD requires not
only comparison between patients with and without recurrence
(which is problematic because some patients without recurrence
at the time of analysis will subsequently develop recurrence) but
also a consistent approach to the diagnostic criteria, and in the
use of protocol biopsies.
AIH: The pathogenesis of recurrent AIH is unclear; recent data sug-
gest that recipient memory T cells might be driving the auto-immune
process, which means that auto-antigenic peptides are being recog-
nized on mismatched donor HLA class 1 and 2 molecules in the graft
[69]. rAIH can occur on the background of immunosuppression that
is adequate to prevent rejection [70]. This might be interpreted as
meaning that such levels of immunosuppression inhibit auto-antigen
speciﬁc T regs leading to subsequent inﬂammation and hepatocyte
injury [71]. Risk factors for recurrence of AIH after OLT have been
assessed in several studies, but most remain unvalidated and contro-
versial. Donor and recipientmatching for HLA-DR3 or DR4 is a contro-
versial risk factor [62,72,73]. The analysis of HLA matching from the
National Institute of Health (NIH) Liver Transplantation Database
showed that HLA-DR locus mismatching was a signiﬁcant risk factor
for recurrence of AIH [74]. A recent study reports that elevated IgG
beforeLTandmoderate tosevere inﬂammation in theexplantareasso-
ciatedwithan increased riskof recurrent autoimmunehepatitis. These
ﬁndings suggest that recurrence of autoimmune hepatitis may
reﬂect incomplete suppression of disease activity prior to LT [75].
PBC: Several studies have shown that tacrolimus-based immu-
nosuppression is associatedwith an increased risk of recurrence of
PBC, with a reduced time to recurrence comparedwith ciclosporin
[76,77]. Whether tacrolimus is truly associated with recurrence or
represents a surrogate of another time-dependent variable is
unknown. The role of genetic factors has not been investigated
thoroughly. The human leukocyte antigen (HLA) proﬁle and HLA
donor-recipient mismatch have controversial association in rPBC
[78–82].Wehave recently identiﬁed the association between rPBC
and a non-HLA locus (rs62270414) in position 3q25, which hosts
the IL12A gene. We found an additive effect between this SNP
and the choice of calcineurin inhibitor at one year with the risk
of rPBC; this is greatest with a combination of tacrolimus at one
year and rs62270414 genotype AG or GG, and least with a combi-
nation of ciclosporin at 1-year and rs62270414 genotype AA [77].
Although these ﬁndings are preliminary and require conﬁrmation,
they are intriguing in that they suggestmechanisms causing PBC in
the allograft and native liver might be similar.
PSC: An intriguing risk factor well documented for rPSC is the
link with IBD. Speciﬁcally, the absence of inﬂammation in the
intestine, either due to absence of concurrent IBD or colectomy
before or during LT has a protective effect against rPSC [83]; this
is in keeping with the hypothesis of aberrant homing of mucosal
lymphocytes to the liver in the development of PSC [84]. How-
ever these ﬁndings were not consistent in all studies. rPSC has
also been associated with acute cellular rejection (ACR), particu-
larly steroid resistant ACR [85–87]. It is currently unknown
whether rPSC results from a response to an immunogenic4 vol. 60 j 210–223 215
Table 2. Published series of recurrent autoimmune liver disease after liver transplantation.






Median time to 
recurrence (mo)
Risk factors
AIH Prados E et al., [146] 1984-1996 27 33 30 Type I (vs. type II) AIH
Milkiewicz P et al., [73] 1982-1998 47 28 29 Donor DR3-/Recipient DR3+
Ratziu V et al., [147] 1985-1992 25 20 24 n.d.
Reich DJ et al., [148] 1988-1995 32 25 15 n.d.
Gonzales-Koch A et al., 
[149]
1985-1998 41 17 52 Recipient HLA DR3/DR4
Montano-Loza AJ., [75] 1989-2008 46 24 30
tion and high IgG levels before LT
PBC Neuberger J et al., [76] 1982-2002 485 23 62 (Tac) Tac-based IMS
123 (CyA)
Abu-Elmagd et al., [150] 1982-1996 421 11 66 Younger age; CIT
Charatcharoenwitthaya P 
et al., [79]
1985-2002 164 34 42 Tac-based IMS
Sanchez EQ et al., [151] 1985-1999 169 11 58 (CyA ± Aza) Tac-based IMS; donor alleles A1, B57, B58, 
DR44, DR57,and DR58; recipient allele B4860 (CyA ± MMF)
24 (Tac ± MMF)
Manousou P et al., [82] 1988-2008 138 26 74 (Aza) n.d.
31 (never on Aza)
Jacob DA et al., [152] 1989-2006 115 14 61 n.d.
Carbone M et al., [77] 1983-2009 248 42 62 Tac-based IMS and genotype AG or GG at 
rs62270414
PSC Goss JA et al., [153] 1984-1996 127 8.6 n.d. n.d.
Jeyarajah DR et al., [154] 1985-1995 100 18 21 (mean) ACR




Vera A et al., [78] 1986-2000 152 37 36 Male sex, intact colon before LT
Campsen J et al., [86] 1988-2006 130 17 n.d. CCA prior to LT (RR 3.77)
Alabraba E et al., [83] 1986-2006 230 23.5 55 Time and type of colectomy; ECD graft
Presence of moderate to severe inflamma-
ACR, acute cellular rejection; AIH, autoimmune hepatitis; Aza, Azathioprine; CCA, cholangiocarcinoma; CyA, Ciclosporin; CIT, cold ischemic time; ECD, extended criteria
donor; HLA, human leukocyte antigen; IBD, inﬂammatory bowel disease; IMS, immunosuppression; LT, liver transplantation; MMF, Mycophenolate Mofetil; n.d., not
determined; Pred, prednisolone; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; Tac, tacrolimus.
Frontiers in Liver Transplantationdamaged biliary system due to ACR, or common factors predis-
pose to both ACR and recurrent disease. Genetic factors that have
been associated with biliary strictures after LT include metallo-
proteinase-2 genotype [88] and CCR5-D32 [89].
A recent series of 114PSC livingdonor LT (LDLT) from Japan [90]
has shown that grafts from ﬁrst-degree-relatives, especially par-
ents, carried the greatest risk of rPSC. A partial explanation may
be that ﬁrst-degree relatives and siblings have a prevalence of
PSC about 100-fold that of nonrelatives [91]. The incidence of
recurrence in recipientswith grafts from related donors other than
parents as well as nonrelated donorswas similar to those reported
for deceased donors LT [87]. Another possiblemechanism contrib-
uting to the effect of ﬁrst-degree-related donorsmight be linked to
the effect of a shared genetic disposition in a blood-related recipi-
ent and donor pair including the HLA system.Rejection after liver transplantation in autoimmune liver
disease
The reported incidence of ACR after LT generally shows a large
variation between different centres and time periods (Table 3),
and this is partially related to evolving immunosuppressive strat-
egies, different policy on protocol biopsies and to a lesser extent,216 Journal of Hepatology 201discrepancies in the diagnostic criteria for rejection. There are rel-
atively few published studies with speciﬁc focus on the incidence
of rejection after LT according to underlying disease, and there
are no studies focused on characterizing histopathological differ-
ences in the inﬂammatory inﬁltrates of ACR in different liver dis-
ease. Based on available data, and the variation in reporting
rejection rates, it is hard to state with certainty that patients
transplanted for autoimmune condition carry a higher risk of
acute cellular rejection (ACR) compared to other patient groups.
However, there is some evidence that patients transplanted
for AILD are more likely to experience ACR compared to those
transplanted for non-autoimmune liver disease. It is of interest
that indications for which there is no evidence of immune
involvement in the pathogenesis of the original liver disease, such
as alcoholic hepatitis and fulminant hepatic failure from paracet-
amol overdose, are associated with the lowest incidence of ACR
[92,93].
AIH: A few series reported that patients transplanted for AIH
were more likely to develop both early acute rejection and late
acute rejection (LAR, acute rejection after 90 days post LT) [94–
98]. One study showed a higher incidence of ACR requiring T cell
depleting antibodies, such as OKT3 treatment, in the ﬁrst
12 months post-OLT [98]. However a higher rate of ACR does
not seem to affect the graft survival. We have recently shown4 vol. 60 j 210–223
Table 3. Published series of acute and chronic rejection in autoimmune liver disease.




Rejection rate (%) Type 
of rejection
Risk factors
AIH Farges O et al., [93] 1984-1992 17 17 Chronic n.d.
Molmenti EP et al., [97] 1984-1998 55 20 Acute n.d.
Wiesner RH et al., [96] 1990-1994 45 60 Acute n.d.
Milkiewicz P et al., [98] 1982-1998 77 15.6 (2% in the control group - 
ALD)
Chronic Younger age and 
histological features of 
moderate or severe ACR
Vogel A et al., [94] 1987-1999 28 82 (50% in the control group - 
Wilson’s and glycogen 
storage disease)
Acute n.d.
14 (8% in the control group) Chronic
Thurairajah PH et al., [92] 2000-2010 46 9 (6% in the control group-HCV) Late Acute n.d.
PBC Farges O et al., [93] 1984-1992 66 1.5 Acute Lack of use of anti-CMV 
polyclonal immunoglobulins
4.5 Chronic n.d.
Milkiewicz P et al., [98] 1982-1998 386 8.2 Chronic n.d.
Seiler CA et al., [95] 1983-1998 22 68 Acute n.d.
Thurairajah PH et al., [92] 2000-2010 165 16 (6% in the control group-HCV) Late acute
PSC McEntee G et al., [157] 1985-1988 44 100 Acute n.d.
Shaked A et al., [158] 1991 36 17 Acute n.d.
Farges O et al., [93] 1984-1992 23 52 Acute n.d.
Narumi S et al., [104] 1988-1993 33 57 Acute IBD
Miki C et al., [105] 1982-1994 55 67 Acute IBD
Wiesner RH et al., [96] 1990-1994 126 46 Acute n.d.
Jeyarajah DR et al., [154] 1985-1995 115 39 Chronic Younger age
Graziadei I et al., [155] 1985-1996 150 69 (59% in the control group) Acute IBD
8 (4.4% in the control group) Chronic
Milkiewicz P et al., [98] 1982-1998 136 7 Chronic n.d.
Bathgate AJ et al., [159] 1992-1998 16 63 Acute n.d.
Brandsaeter B et al., 
[160]
1984-2003 49 71 (51% in the control group) Acute n.d.
Thurairajah PH et al., [92] 2000-2010 87 14 (6% in the control group-HCV) Late acute n.d.
ACR, acute cellular rejection; ALD, alcoholic liver disease; CMV, cytomegalovirus; HCV, hepatitis C virus; IBD, inﬂammatory bowel disease; n.d., not determined.
JOURNAL OF HEPATOLOGYin the Birmingham cohort (period 2000–2010) that the risk of
developing LAR was not increased in those transplanted for
AIH. This might be explained by the policy of long-term steroid
treatment in patients transplanted for AIH introduced in Birming-
ham after 2000 [92]. Unfortunately, patients transplanted for AIH
have been shown to have a higher frequency of chronic ductope-
nic rejection (CR) or ‘ductopenia’, which affects more than 50% of
portal tracts and an obliterative arteriopathy affecting large- and
medium-sized arteries, which occur generally after the ﬁrst year
post-LT [93,98]. Data from an older cohort in Birmingham (period
1982–1998) showed that patients transplanted for AIH, who
developed CR were younger than other AIH patients at LT and
more often had histological features of moderate to severe acute
rejection on early post-LT biopsies [98]. Risk factors for CR in AIH
have not been reported in other series. The impact of improve-
ments in immunosuppression on the risk of CR remains
uncertain.
PBC: There are reports showing patients transplanted for
PBC suffer more frequently from ACR [98,95,98–101]. We
recently reported that PBC recipients have one of the highest
risks of LAR, with an odds ratio of 2.1, compared to those with
hepatitis C that had the lowest risk of LAR. A pre-LT diagnosis
of PBC and a young recipient age were the only independentJournal of Hepatology 201predictors of LAR in the Cox logistic regression model. In this
study, graft survival was worse in those with LAR, but we have
not speciﬁcally assessed the outcome of those transplanted for
PBC [92].
PSC: Many older series have reported a higher incidence of
ACR in patients transplanted for PSC [100,102]. Again, the num-
ber of ACR episodes had no impact on patient or graft survival
but such an effect may be masked by relatively small numbers
and the heterogeneity of patients. In our recent Birmingham
cohort those transplanted for PSC had one of the highest risks
of LAR with an OR of 1.8 [92]. There are conﬂicting data about
whether the presence of IBD has an adverse impact on the risk
of rejection of PSC after the transplantation. Some groups have
reported a higher incidence of ACR in PSC patients with ulcer-
ative colitis (UC) compared with PSC patients without UC
[96,103–105]. These data were not conﬁrmed in other cohorts
[106].
The reason why patients with AILD might have an increased
frequency of rejection is not clear. There are recent data from
the lung transplantation ﬁeld suggesting that pre-existing
immune response to self-antigens might augment the risk of
developing alloimmune response to mismatched donor antigens













Fig. 3. Hypothetical link between autoimmunity and alloimmunity mechanisms after liver transplantation for autoimmune liver disease.
Frontiers in Liver TransplantationNK cells may be important because of their ability to recog-
nize allogeneic MHC antigens and their potent cytolytic activ-
ity; they have emerged as a focus of interest in the
transplant ﬁeld as they might participate in the immune
response in both acute and chronic rejection of solid organ
allografts [110]. They possess a variety of inhibitory and acti-
vating receptors, such as the KIRs, which recognize MHC class
I molecules and kill target cells that display reduced levels of
MHC class I antigens. There is evidence that KIR interaction
with donor HLA-C ligands leads to a differential degree of NK
cell inhibition and this might inﬂuence the development and
degree of CR, subsequent ﬁbrosis and outcome of the allograft
[111]. However, the effect of NK epitope mismatching on ACR
after LT is uncertain. Modulation of KIR and donor HLA (partic-
ularly HLA-C) interactions might represent an important novel
approach to promote long-term graft and patient survival after
organ transplantation. This is of interest since particular combi-
nations of KIRs and HLA class I ligands that reduce NK cell
inhibition have been shown to increase the susceptibility to
autoimmune diseases in general [112]; speciﬁcally, particular
genetic variants of ligands for NK cell receptors might increase
the risk of PSC [113]. Consistent with this, an increase in NK
cells in the liver in PSC, compared with other liver diseases
has been described [114]. NK cells have been called into ques-
tion in PBC, since they have been shown to be involved in the
destruction of cholangiocytes, and NK-T cells are partly
responsible for the exacerbation of disease in PBC [115–117].
Furthermore, a marked suppression of anti-mitochondrial auto-







Kerkar N et al., [161] 1991-1996 180 8.3
Gupta P et al., [162] 1995-2000 115 2.2
Miyagawa-Hayashino A et al., [125] 1990-2002 633 10
Venick RS et al., [126] 1984-2003 619 3.6 (mea
Eguchi S et al., [163] 1997-2007 72 45
Cho JM et al., [164] 1994-2007 149 12.4*
Hernandez HM et al., [165] 1990-1999 155 3.5
⁄Age at presentation; age at transplant not reported in the original paper.
AIH, autoimmune hepatitis.
218 Journal of Hepatology 201cells has been shown in a murine model of PBC following in-
vivo depletion of NK and NK-T cells [118]. These data overall
imply a major role for NK cells effector mechanisms in the
pathogenesis of AILD. These might represent some of the effec-
tors of a ‘crosstalk’ between alloimmune response and autoim-
mune response after organ transplant that perpetuate each
other, and could in part explain why those transplanted for
AILD are more likely to experience rejection (Fig. 3).
While early ACR does not seem to impact on long-term out-
come, CR is much more closely associated with graft failure. It
was previously assumed that mainly alloimmune responses con-
tribute to the pathogenesis of CR. However, more recent ﬁndings,
particularly in the ﬁeld of lung transplantation, demonstrate that
autoimmunity to tissue-restricted self-antigens may contribute
to the immunopathogenesis of CR following transplantation
[109]. Some authors have therefore proposed that the autoim-
mune component should be recognized in the pathogenesis of
CR and be considered in developing new strategies for preventing
and/or treating CR following transplantation.De novo autoimmune hepatitis after liver transplantation
A clinical entity sharing the biochemical, immunological, and his-
tological characteristics of AIH, called de novo AIH (dn-AIH), has
been well described in adults and children undergoing LT for a
range of diseases unrelated to autoimmunity [119] (Table 4).
The clinical manifestations of dn-AIH are similar to those of recur-
rent AIH including a prominent plasma cell inﬁltratewith interfacege 
nt at transplant (yr)
Frequency 
(%)
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hepatitis, hypergammaglobulinaemia, increased serum IgG levels,
and autoantibodies. Dn-AIH has also been diagnosed in the
absence of autoantibodies [120] and in some patients without
increased serum IgG levels or autoantibodies [121]. Such varia-
tions in diagnoses makes assessment of the literature challenging.
Dn-AIH generally presents after one year post-LT and usually
responds well to increased immunosuppression, but some cases
progress to cirrhosis or graft failure [122]. As in recurrent autoim-
mune hepatitis, the HLA status of the recipient [123], the duration
after LT [124], and thenumberof rejectionepisodes [125,126] have
been proposed as contributing factors, but none of these has been
consistently recognized as predictive of its occurrence. However,
weaning from corticosteroid therapy does not seem to be a trigger.
The immune response in dn-AIH may be directed against allo-
antigens, neo-antigens, or self-antigens. An alloantigen in dnAIH
has been identiﬁed in the glutathione-S-transferase T1 (GSTT1),
which is an alloantigen present in some individuals and that gener-
ates alloantibodies in those who lack it [127]. The gene that encodes
GSTT1 is absent in 20% of the white population, and GSTT1 donor/
recipient genotypemismatch has been suggested as a necessary con-
dition for the appearance of autoantibodies and de novo AIH [127].
However, dn-AIH has also been described in the absence of a GSTT1
mismatch [128]. There is evidence that the choice of calcineurin
inhibitor may inﬂuence the development of de novo AIH mediated
by anti-GSTT1 antibodies, with patients treatedwith tacrolimus hav-
ing a loweroccurrence [129]. Theseobservations support the concept
that dn-AIH may represent an alloimmune response (i.e., a form of
rejection), in which immune-mediated injury is directed towards
hepatocytes rather than bile ducts or vascular endothelium; and
GSTT1 might represent not the only alloantigen that can trigger an
autoimmune response. Further support for an alloimmune mecha-
nism in dn-AIH is the strong correlation with previous rejection his-
tory and steroid dependence [130].
Alternatively, the inﬂammatory response within the donor
liver may also unmask neo-antigens and intensify the co-stimu-
latory signals that activate lymphocytes [131–133].
Some argue that the immune response in de-AIHmay be direc-
ted against self-antigens. It has been shown that bronchial
administration of anti-MHC class I antibodies in the native lungs
of HLA-mismatchedmice induced bronchiolar scarring, amanifes-
tationof chronic allograft rejection in the lung; this is accompanied
by up-regulation of IL17 and de novo antibody formation to the
self-antigens, such as K-a 1-tubulin, and collagen V, also seen in
chronic human lung rejection [134]. Authors have hypothesised
that chronic alloimmune injury may release protected self-anti-
gens, which elicit autoantibody formation, and that the cycle
may be perpetuated by ongoing IL17 signaling, a known facilitator
of alloimmunity and autoimmunity. Further supporting the auto-
immune hypothesis is the presence of a plasma cell inﬂammatory
inﬁltrates, hallmark of autoimmune injury, and the fact that anti-
MHC class I antibodies fail to induce bronchiolar scarring in B cell
deﬁcient mice [135].
Some experts argue that rejection and dn-AIH are part of the
same spectrum [136]; rejection during the early stage post-trans-
plant is driven by an MHC-restricted and epitope speciﬁc process;
the resultantgraft damagemay lead toT cell responses toother graft
antigens and breaks tolerance to self-antigens leading to dn-AIH.
An autoimmune-like hepatitis has also been described in LT
recipients treated with PegIFN and RBV for recurrent hepatitis
C, with no history of AILD [137].Journal of Hepatology 201Histological ﬁndings are an essential element in the differential
diagnosis between dn-AIH, ACR, LAR, and CR. The higher propor-
tion of plasma cells and the severity of the interface activity (more
typical in AIH) and the prevalence of bile duct damage (character-
istic of rejection) are currently used as markers, albeit imprecise
ones. However, no accurate limit for the percentage of plasma cells
has been established, and none of these criteria have been tested
prospectively for reproducibility, predictive value, or an associa-
tion with serological evidence of autoimmunity. The time interval
between disease occurrence and LT is another important diagnos-
tic clue [138]. Diagnostic difﬁculties arise when ACR, CR or AIH
develop at uncharacteristic intervals after LT [139,140] or when
histological manifestations of graft dysfunction are atypical
[141,142] or inexplicable [138,143,144]. Future studies aimed at
investigating the role of autoantibody and the antigenic speciﬁcity
of the liver-inﬁltrating lymphocytes in patients with autoimmune
disorder after LT are therefore warranted.
Key Points
• GWAS and iCHIP-association studies in PBC and
PSC have improved our knowledge of the genetic
architecture of these diseases, highlighting specific
pathogenetic pathways in both innate and acquired
immune response. Studying gene-gene interaction,
gene-environment interaction and epigenetic
mechanisms is the best way forward to clarify what is
still poorly understood in the pathogenesis of AILD
• There is a remarkable overlap of genetic susceptibility
factors between different autoimmune conditions. This
suggests distinct mechanisms, by which autoimmunity
occurs, each mechanism predisposing to a particular
phenotype or set of phenotypes. It follows that there
might be unique immunologic pathways that we have
to focus on for therapeutic intervention
• Outcomes after liver transplantation for AILD are
generally favourable. The original autoimmune
disease recurs in a considerable number of recipients.
Currently, graft loss due to recurrent disease 
represents a major issue only in PSC. However,
prevention of recurrent PSC is limited by the lack of a
clear understanding of the disease in the native liver
• Patients transplanted for AILD seem to have a higher
risk of acute rejection. A crosstalk between alloimmune
response and autoimmune response after liver
transplantation that perpetuate each other might, in
part, explain this. It is recognized, however, that acute
rejection does not affect long-term survival. Of more
concern is the evidence of an increased risk of chronic
ductopenic rejection, which is a major cause of graft
loss. An autoimmune component should be recognized
also in the pathogenesis of chronic rejection
• De novo autoimmune hepatitis (dn-AIH) after LT is
a well described entity in patients undergoing LT
for a range of diseases unrelated to autoimmunity,
particularly in the pediatric setting. It is not entirely
clear whether the immune response is directed against
allo-antigens, neo-antigens, or self-antigens4 vol. 60 j 210–223 219
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Conclusions
AILD remains a good indication for LT with excellent patient and
graft outcomes. Recurrence of the original disease, particularly of
PSC, represents a signiﬁcant cause of graft loss after LT. Preven-
tive or therapeutic strategies are limited by the lack of a full
understanding of the disease pathogenesis in the native liver.
LT provides a unique setting to help understand the pathophysi-
ology of AILD. However, variations in clinical practice and the use
of protocol liver biopsies means that the understanding of the
severity and risk factors for recurrent disease and evaluation of
therapeutic interventions is, at best, limited.
A higher risk of both acute cellular and ductopenic rejection is
a further challenge in patients transplanted for autoimmune con-
ditions. Early ACR does not impact negatively on long-term out-
come and may promote tolerance, while CR is a rare but
important cause of late graft dysfunction and graft loss. Immuno-
logical factors responsible for the original liver disease may be
active post-transplant and potentially act as a predisposing con-
dition for acute and chronic rejection.Conﬂict of interest
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